An Open Label Phase IIa Clinical Study to Evaluate the Safety and Pharmacokinetics of Intravenous and Oral F901318 (Combined With Caspofungin) for Antifungal Prophylaxis in Patients Undergoing Chemotherapy for Acute Myeloid Leukaemia
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- Collection of adverse events, results of physical examination, vital signs, ECGs, and laboratory assessments during F901318 intravenous infusion and oral formulation.
研究概览
简要总结
This study assesses the pharmacokinetics and safety of the new antifungal F901318 in AML patients.
详细描述
F901318 has potent in vitro efficacy against Aspergillus spp. including azole-resistant strains and consistent efficacy in in vivo mouse models of infection. F901318 is active by both oral and intravenous routes of administration in preclinical efficacy studies.
Non-clinical studies and phase I clinical trials show that F901318 has a good overall safety profile and limited potential for drug-drug interactions. F901318 exhibits a highly promising profile which can potentially address the critical treatment requirements for invasive Aspergillus infections in a changing clinical environment in which new classes of antifungals are needed.
This phase IIa study aims to confirm PK and safety information of F901318 from phase I and bridge them to a neutropenic AML patient population, which represents the main population for future efficacy trials. Coadministration of caspofungin will allow recognizing potential factors of suboptimal F901318 exposure without the risk of fatal disseminating infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with AML and entering treatment of chemotherapy.
- •Patients are expected to be neutropenic (< 500 ANC/μl) for > 10 days.
- •Provision of written informed consent prior to any study specific procedures.
- •Ability and willingness to comply with the protocol.
- •Patients aged over 18 years.
- •Patient has or will receive within 2 days a multi-lumen central venous catheter as standard of care.
排除标准
- •Documented lung infiltrate at screening.
- •Documented serum GMI ≥0.5 at screening
- •Current IFD or prior history of IFD or patients who received systemic antifungal therapy for proven or probable IFD in the last 12 months.
- •Patients who received any systemic antifungal therapy for more than 72 hours immediately prior to first administration of study medication. Echinocandins and topical polyenes or nystatin are acceptable. Posaconazole and other azoles have to be discontinued at least 3 days before start of F
- •Concomitant exposure to phenobarbital and long acting barbiturates, triazolam, carbamazepine, phenytoin, pimozide, cisapride, efavirenz, ritonavir, rifabutin, rifampicin, ergot alkaloids (ergotamine, dihydroergotamin), ibrutinib, idelalisib, vinca alkaloids, digoxin, dofetilide, quinidine, St. John´s wort, everolimus, sirolimus, astemizole, terfenadine, methadone, alfentanil, fentanyl and other structurally related opiates, warfarin.
- •Documented prolongation of the QTc interval (>450 ms).
- •Concomitant medication that prolongs QT interval (except for cytostatic drugs used during chemotherapy, such as mitoxantrone).
- •Any other concomitant medical condition that, in the opinion of the investigator, may be an unacceptable additional risk to the patient should he/she participate in the study.
- •History of convulsion.
- •Female patients only: Positive result of pregnancy test or breastfeeding.
- •Female patients of childbearing potential who do not agree to not have sexual intercourse during the study or who do not use or do not agree to use appropriate contraceptive methods (prior to and during the study, including 14 days after the last dose of study therapy) as defined in ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals (EMA/CPMP/ICH/286/1995). Hormonal contraception alone is not considered appropriate.
- •Known hypersensitivity to any component of the study medication.
- •A history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalaemia, cardiomyopathy, sinus bradycardia, symptomatic arrhythmias, family history of long QT Syndrome).
- •Patient has had acute hepatitis in the prior 6 months, chronic hepatitis, cirrhosis (any Child-Pugh class), acute hepatic failure, or acute decompensation of chronic hepatic failure
- •Presence of hepatic disease as indicated by aspartate aminotransferase (AST) or alanine transaminase (ALT)>3 × upper limit of normal (ULN) at Screening. Patients with AST and/or ALT >3 × ULN and <5 × ULN are eligible if these elevations are acute, not accompanied by a total bilirubin ≥2xULN and documented by the investigator as being directly related to an infectious process being treated. During the clinical study, the investigator is responsible for, without delay, determining whether the patient meets potential Hy's law criteria (according to FDA [28]).
- •Patient has a total bilirubin >3 × ULN, unless isolated hyperbilirubinemia is directly related to an acute infection or due to known Gilbert's disease.
- •Calculated creatinine clearance (CrCl) < 50 mL/minute.
- •Medical history of oliguria (< 20 mL/h) unresponsive to fluid challenge.
- •Suspected other or additional cause for neutropenia or immunosuppression (other than AML or myelodysplastic syndrome).
- •Any other medical condition which may affect the clinical evaluability of the patient.
- •Patients previously enrolled in this study.
- •Patient has participated or intends to participate in any other clinical study that involves the administration of an investigational medication at the time of presentation, during the course of the study, or during the 30 days prior to study start. New combinations of labelled substances for chemotherapy are allowed.
- •Chronic ocular disease.
- •Contact lens use intended during study treatment.
研究组 & 干预措施
F901318 + Caspofungin
Patients will receive F901318 intravenously, starting 24 - 72 h after last chemotherapy infusion:
- Day 1: 4.0 mg/kg i.v. b.i.d.
- Day 2 until resolution of neutropenia (max. until day 14): 2.0 mg/kg i.v. b.i.d.
- Day after last i.v. application: 2.0 mg/kg oral q.d.
Concomitant medication:
For Candida prophylaxis, concomitant caspofungin will be administered from the 4th day of chemotherapy until end of neutropenia:
- Chemo day 4: Caspofungin 70 mg i.v. q.d.
- Chemo day 5 until resolution of neutropenia or until end of F901318 treatment (day 15): Caspofungin 50 mg i.v. q.d.
All patients will undergo chemotherapy for acute leukaemia according to local clinical standard.
干预措施: F901318 (Drug)
F901318 + Caspofungin
Patients will receive F901318 intravenously, starting 24 - 72 h after last chemotherapy infusion:
- Day 1: 4.0 mg/kg i.v. b.i.d.
- Day 2 until resolution of neutropenia (max. until day 14): 2.0 mg/kg i.v. b.i.d.
- Day after last i.v. application: 2.0 mg/kg oral q.d.
Concomitant medication:
For Candida prophylaxis, concomitant caspofungin will be administered from the 4th day of chemotherapy until end of neutropenia:
- Chemo day 4: Caspofungin 70 mg i.v. q.d.
- Chemo day 5 until resolution of neutropenia or until end of F901318 treatment (day 15): Caspofungin 50 mg i.v. q.d.
All patients will undergo chemotherapy for acute leukaemia according to local clinical standard.
干预措施: Caspofungin (Drug)
结局指标
主要结局
Collection of adverse events, results of physical examination, vital signs, ECGs, and laboratory assessments during F901318 intravenous infusion and oral formulation.
时间窗: 57 days
次要结局
- Concentration-time profile of F901318 following i.v. administration(14 days)
- Measured concentration of F901318 at the end of an i.v. dosing interval at steady state (Ctrough)(14 days)
- Minimum observed plasma or serum, concentration of F901318 during an i.v. dosing interval at steady state (Cmin, ss)(14 days)
- Maximum observed plasma or serum, concentration of F901318 during an i.v. dosing interval at steady state (Cmax, ss)(14 days)
- Area under the concentration vs. time curve from point zero up to the end of infusion of F901318 (AUC(0-T))(14 days)
- Area under the concentration vs. time curve from time point zero up to the time point t (AUC(0-t)) for F901318 after i.v. administration(14 days)
- Apparent terminal half-life (t1/2) of F901318 after i.v. administration(14 days)
- Terminal rate constant (λz) of F901318 after i.v. administration(14 days)
- Average plasma or serum concentration of F901318 at steady state after i.v. administration (Cav,ss)(14 days)
- Area under the concentration-time curve during a F901318 i.v. dosing interval at steady state calculated by trapezoidal rule (AUCT,ss)(14 days)
- Area under the concentration vs. time curve from time point zero up to the last measured concentration of F901318 above LOQ (AUC(0-t_last)) after i.v. administration(14 days)
- Apparent clearance (Cl) of F901318 after i.v. administration(14 days)
- Plasma concentration of F901318 after oral application(1 day)
- Number of patients developing an possible/probable/proven invasive fungal disease (IFD) according to EORTC/MSG criteria(57 days)